Health Care • Medical/Dental Instruments
$13.23 ▼ -0.12
(-0.90%)
MKT CAP: $1.22B • VOL: 293.6K
52W L $3 52W H $16
ROARABLE / RQD
E • 33/100
PIOTROSKI
2 / 9
DRTS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$42.3M | -$36.0M | -$35.7M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$42.6M | -$31.8M | -$29.2M |
| EBITDA (Normalized) | -$37.4M | -$34.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$26.7M | -$19.8M | -$18.0M |
| Capital Expenditures (CapEx) | $6.1M | $2.2M | — |
| Free Cash Flow (FCF) | -$32.8M | -$22.0M | -$18.0M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $12.2M | $13.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $77.1M | $62.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR DRTS.